Troy Chambers
Supervisory Patent Examiner (ID: 10220, Phone: (571)272-6874 , Office: P/3641 )
Most Active Art Unit | 3641 |
Art Unit(s) | 3641, 3658 |
Total Applications | 1138 |
Issued Applications | 714 |
Pending Applications | 107 |
Abandoned Applications | 317 |
Applications
Application number | Title of the application | Filing Date | Status |
---|---|---|---|
Array
(
[id] => 18656056
[patent_doc_number] => 20230301922
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-28
[patent_title] => Layered Pharmaceutical Formulations
[patent_app_type] => utility
[patent_app_number] => 18/143254
[patent_app_country] => US
[patent_app_date] => 2023-05-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9802
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -33
[patent_words_short_claim] => 75
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18143254
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/143254 | Layered Pharmaceutical Formulations | May 3, 2023 | Pending |
Array
(
[id] => 18842582
[patent_doc_number] => 20230404986
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-12-21
[patent_title] => COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1 AND/OR PD-L1 INHIBITOR
[patent_app_type] => utility
[patent_app_number] => 18/311815
[patent_app_country] => US
[patent_app_date] => 2023-05-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17642
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 92
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18311815
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/311815 | COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1 AND/OR PD-L1 INHIBITOR | May 2, 2023 | Pending |
Array
(
[id] => 18784732
[patent_doc_number] => 20230372347
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-23
[patent_title] => INDUCTION OF IMMUNE TOLERANCE BY USING METHOTREXATE
[patent_app_type] => utility
[patent_app_number] => 18/141128
[patent_app_country] => US
[patent_app_date] => 2023-04-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22294
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18141128
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/141128 | INDUCTION OF IMMUNE TOLERANCE BY USING METHOTREXATE | Apr 27, 2023 | Pending |
Array
(
[id] => 18901329
[patent_doc_number] => 20240016814
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-01-18
[patent_title] => METHOD OF TREATING HYPERTENSION
[patent_app_type] => utility
[patent_app_number] => 18/301643
[patent_app_country] => US
[patent_app_date] => 2023-04-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9025
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18301643
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/301643 | METHOD OF TREATING HYPERTENSION | Apr 16, 2023 | Pending |
Array
(
[id] => 18550739
[patent_doc_number] => 20230248739
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-10
[patent_title] => METHODS OF TREATING CORTICAL DEMENTIA ASSOCIATED WANDERING
[patent_app_type] => utility
[patent_app_number] => 18/300445
[patent_app_country] => US
[patent_app_date] => 2023-04-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12568
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 23
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18300445
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/300445 | METHODS OF TREATING CORTICAL DEMENTIA ASSOCIATED WANDERING | Apr 13, 2023 | Pending |
Array
(
[id] => 18509978
[patent_doc_number] => 20230226073
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-20
[patent_title] => METHODS OF TREATING PROTEINOPATHY ASSOCIATED WANDERING
[patent_app_type] => utility
[patent_app_number] => 18/189478
[patent_app_country] => US
[patent_app_date] => 2023-03-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11804
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 48
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18189478
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/189478 | METHODS OF TREATING PROTEINOPATHY ASSOCIATED WANDERING | Mar 23, 2023 | Pending |
Array
(
[id] => 18466957
[patent_doc_number] => 20230201237
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-29
[patent_title] => RESPONSE-GUIDED HCV THERAPY
[patent_app_type] => utility
[patent_app_number] => 18/111350
[patent_app_country] => US
[patent_app_date] => 2023-02-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22537
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 70
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18111350
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/111350 | RESPONSE-GUIDED HCV THERAPY | Feb 16, 2023 | Pending |
Array
(
[id] => 18815902
[patent_doc_number] => 20230390241
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-12-07
[patent_title] => DASH INHIBITORS, AND USES RELATED THERETO
[patent_app_type] => utility
[patent_app_number] => 18/111143
[patent_app_country] => US
[patent_app_date] => 2023-02-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 48013
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18111143
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/111143 | DASH INHIBITORS, AND USES RELATED THERETO | Feb 16, 2023 | Pending |
Array
(
[id] => 18784680
[patent_doc_number] => 20230372286
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-23
[patent_title] => COMPOSITION COMPRISING NAPHTHOQUINONE-BASED COMPOUND AS ACTIVE INGREDIENT, FOR PREVENTING OR AMELIORATING FATIGUE, CACHEXIA, PAIN, COGNITIVE DECLINE AND HEMATOPOIETIC STEM CELL REDUCTION WHICH ARE SIDE EFFECTS RELATED TO ANTICANCER DRUG TREATMENT
[patent_app_type] => utility
[patent_app_number] => 18/151265
[patent_app_country] => US
[patent_app_date] => 2023-01-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17609
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 65
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18151265
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/151265 | COMPOSITION COMPRISING NAPHTHOQUINONE-BASED COMPOUND AS ACTIVE INGREDIENT, FOR PREVENTING OR AMELIORATING FATIGUE, CACHEXIA, PAIN, COGNITIVE DECLINE AND HEMATOPOIETIC STEM CELL REDUCTION WHICH ARE SIDE EFFECTS RELATED TO ANTICANCER DRUG TREATMENT | Jan 5, 2023 | Pending |
Array
(
[id] => 18769315
[patent_doc_number] => 20230364073
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-16
[patent_title] => PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CFTR MEDIATED DISEASES
[patent_app_type] => utility
[patent_app_number] => 18/091472
[patent_app_country] => US
[patent_app_date] => 2022-12-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 37819
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18091472
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/091472 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CFTR MEDIATED DISEASES | Dec 29, 2022 | Pending |
Array
(
[id] => 18434303
[patent_doc_number] => 20230181597
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-15
[patent_title] => METAL COMPLEXES OF NOCARDAMINE AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS
[patent_app_type] => utility
[patent_app_number] => 18/087564
[patent_app_country] => US
[patent_app_date] => 2022-12-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 35021
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18087564
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/087564 | METAL COMPLEXES OF NOCARDAMINE AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS | Dec 21, 2022 | Pending |
Array
(
[id] => 18434240
[patent_doc_number] => 20230181534
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-15
[patent_title] => USE OF A PROTEASOME INHIBITOR FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM (CNS) CANCERS
[patent_app_type] => utility
[patent_app_number] => 18/076256
[patent_app_country] => US
[patent_app_date] => 2022-12-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 45359
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18076256
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/076256 | USE OF A PROTEASOME INHIBITOR FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM (CNS) CANCERS | Dec 5, 2022 | Pending |
Array
(
[id] => 18250748
[patent_doc_number] => 20230077787
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-16
[patent_title] => BUPRENORPHINE DOSING REGIMENS
[patent_app_type] => utility
[patent_app_number] => 17/985253
[patent_app_country] => US
[patent_app_date] => 2022-11-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15165
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17985253
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/985253 | BUPRENORPHINE DOSING REGIMENS | Nov 10, 2022 | Pending |
Array
(
[id] => 18589158
[patent_doc_number] => 11738030
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-08-29
[patent_title] => Treatments for disturbed cerebral homeostasis
[patent_app_type] => utility
[patent_app_number] => 18/047276
[patent_app_country] => US
[patent_app_date] => 2022-10-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 3
[patent_no_of_words] => 23683
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 62
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18047276
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/047276 | Treatments for disturbed cerebral homeostasis | Oct 17, 2022 | Issued |
Array
(
[id] => 18091262
[patent_doc_number] => 20220409603
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-29
[patent_title] => OPHTHALMIC COMPOSITION
[patent_app_type] => utility
[patent_app_number] => 17/894882
[patent_app_country] => US
[patent_app_date] => 2022-08-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 49325
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 91
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17894882
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/894882 | OPHTHALMIC COMPOSITION | Aug 23, 2022 | Pending |
Array
(
[id] => 18091263
[patent_doc_number] => 20220409604
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-29
[patent_title] => OPHTHALMIC COMPOSITION
[patent_app_type] => utility
[patent_app_number] => 17/894884
[patent_app_country] => US
[patent_app_date] => 2022-08-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 49289
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 68
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17894884
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/894884 | OPHTHALMIC COMPOSITION | Aug 23, 2022 | Pending |
Array
(
[id] => 18091264
[patent_doc_number] => 20220409605
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-29
[patent_title] => OPHTHALMIC COMPOSITION
[patent_app_type] => utility
[patent_app_number] => 17/894885
[patent_app_country] => US
[patent_app_date] => 2022-08-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 49417
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 52
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17894885
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/894885 | OPHTHALMIC COMPOSITION | Aug 23, 2022 | Pending |
Array
(
[id] => 18296183
[patent_doc_number] => 20230105869
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-06
[patent_title] => C5aR INHIBITOR REDUCTION OF URINARY sCD163
[patent_app_type] => utility
[patent_app_number] => 17/815992
[patent_app_country] => US
[patent_app_date] => 2022-07-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9443
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17815992
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/815992 | C5aR INHIBITOR REDUCTION OF URINARY sCD163 | Jul 28, 2022 | Pending |
Array
(
[id] => 18003618
[patent_doc_number] => 20220362384
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-17
[patent_title] => COMPOSITION FOR TREATING OR PREVENTING CLIMACTERIC DISORDERS
[patent_app_type] => utility
[patent_app_number] => 17/848554
[patent_app_country] => US
[patent_app_date] => 2022-06-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6207
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 107
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17848554
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/848554 | COMPOSITION FOR TREATING OR PREVENTING CLIMACTERIC DISORDERS | Jun 23, 2022 | Pending |
Array
(
[id] => 18091223
[patent_doc_number] => 20220409564
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-29
[patent_title] => DOSAGE FORMS AND THERAPEUTIC USES OF L-4-CHLOROKYNURENINE
[patent_app_type] => utility
[patent_app_number] => 17/845105
[patent_app_country] => US
[patent_app_date] => 2022-06-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4762
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 21
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17845105
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/845105 | Dosage forms and therapeutic uses of L-4-chlorokynurenine | Jun 20, 2022 | Issued |